IOVANCE BIOTHERAPEUTICS, INC.
Company Stats
- Market Cap
- $6.7B
- as of Sep 30, 2026
- Shares Outstanding
- 453.0M
- Free Float
- 84.6%
Income Statement
- Revenue
- $263.5M
- Operating Income
- -$403.4M
- Net Income
- -$391.0M
- EBITDA
- -$390.5M
- FCF Margin, 3Y Avg
- -10884.9%
- FCF Margin, Worst Year
- -32305.3%
Cash Flow
- Free Cash Flow
- -$336.2M
- FCF Yield
- -5.0%
- Owner FCF Yield
- -5.9%
Balance Sheet
- Cash & Equivalents
- $163.1M
Returns & Capital
- SBC, 3Y Avg
- $77.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $263.5M | -$336.2M | -127.6% |
| FY2024 | $164.1M | -$364.0M | -221.9% |
| FY2023 | $1.2M | -$384.1M | -32305.3% |
| FY2022 | — | -$313.2M | — |
| FY2021 | — | -$265.5M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back